MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Abbott Laboratories

Fechado

SetorSaúde

123.73 2.37

Visão Geral

Variação de preço das ações

24h

Atual

Mín

123.53

Máximo

124.48

Indicadores-chave

By Trading Economics

Rendimento

-7.9B

1.3B

Vendas

-616M

10B

P/E

Médio do Setor

17.147

39.857

EPS

1.09

Rendimento de Dividendos

1.74

Margem de lucro

12.792

Funcionários

114,000

EBITDA

-324M

2.7B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+17.79% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.74%

2.42%

Próximos Ganhos

15 de out. de 2025

Próxima data de dividendos

15 de ago. de 2025

Próxima data de ex-dividendo

14 de out. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.9B

230B

Abertura anterior

121.36

Fecho anterior

123.73

Sentimento de Notícias

By Acuity

41%

59%

138 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Abbott Laboratories Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de jul. de 2025, 12:10 UTC

Ganhos

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

16 de abr. de 2025, 16:21 UTC

Ganhos

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

16 de abr. de 2025, 12:14 UTC

Ganhos

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

17 de jul. de 2025, 13:14 UTC

Ganhos

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 de jul. de 2025, 12:16 UTC

Ganhos

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

17 de jul. de 2025, 11:32 UTC

Ganhos

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

17 de jul. de 2025, 11:32 UTC

Ganhos

Abbott Labs: See Momentum Carrying Into 2026 >ABT

17 de jul. de 2025, 11:31 UTC

Ganhos

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Sales $11.14B >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Net $1.78B >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q Adj EPS $1.26 >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

17 de jul. de 2025, 11:30 UTC

Ganhos

Abbott Labs 2Q EPS $1.01 >ABT

17 de jul. de 2025, 09:08 UTC

Ações em Alta

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

1 de jul. de 2025, 18:41 UTC

Aquisições, Fusões, Aquisições de Empresas

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

16 de abr. de 2025, 15:09 UTC

Conversa de Mercado

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

16 de abr. de 2025, 14:17 UTC

Ganhos

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

16 de abr. de 2025, 11:34 UTC

Ganhos

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

16 de abr. de 2025, 11:33 UTC

Ganhos

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

16 de abr. de 2025, 11:32 UTC

Ganhos

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

16 de abr. de 2025, 11:32 UTC

Ganhos

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

16 de abr. de 2025, 11:31 UTC

Ganhos

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

16 de abr. de 2025, 11:30 UTC

Ganhos

Abbott Reaffirms Full-Yr Guidance

16 de abr. de 2025, 11:30 UTC

Ganhos

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

16 de abr. de 2025, 11:30 UTC

Ganhos

Abbott Labs 1Q Sales $10.36B >ABT

16 de abr. de 2025, 11:30 UTC

Ganhos

Abbott Labs 1Q Net $1.33B >ABT

Comparação entre Pares

Variação de preço

Abbott Laboratories Previsão

Preço-alvo

By TipRanks

17.79% parte superior

Previsão para 12 meses

Média 145.67 USD  17.79%

Máximo 159 USD

Mínimo 135 USD

Com base em 19 analistas de Wall Street que oferecem metas de preço de 12 meses para Abbott Laboratories - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

19 ratings

16

Comprar

3

Manter

0

Vender

Pontuação Técnica

By Trading Central

132.82 / 134.43Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

138 / 376 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.